Group 1 - The core point of the article is that Microchip Biotech (688321.SH) has signed a licensing and distribution agreement with Nizhny Novgorod Chemical Pharmaceutical Plant (Nizhpharm) for the product Chidamide, granting Nizhpharm exclusive rights for research, registration, and commercialization in several countries [1][2] - Nizhpharm will be responsible for the research, market registration, secondary packaging, transportation, and commercialization of Chidamide in the authorized regions [1][2] - The agreement includes an initial payment of 10 million RMB and additional milestone payments totaling 10 million RMB for local registration and market launch [2] Group 2 - Nizhpharm is one of the leading pharmaceutical companies in the Russian Federation, with over a century of history, focusing on unmet medical needs in key therapeutic areas [2] - Chidamide is the world's first subtype-selective histone deacetylase (HDAC) inhibitor, marking a significant milestone for Chinese innovative drugs in licensing out to Europe and the United States [2] - The company will receive a high double-digit percentage of sales revenue based on the net sales achieved in the authorized regions from Nizhpharm [2]

Core Insights - The Hang Seng Innovation Drug Index fell by 4.8% this week, while the CSI Hong Kong Pharmaceutical and Health Comprehensive Index decreased by 3.2%. In contrast, the CSI Innovation Drug Industry Index rose by 1.1%, the CSI Biotechnology Theme Index increased by 1.3%, and the CSI 300 Pharmaceutical and Health Index grew by 1.7% [1][3]. Index Performance - As of August 28, the Hang Seng Innovation Drug ETF (159316) has seen continuous capital inflow, reaching a record size of over 1.7 billion yuan [1]. - The rolling P/E ratios for various indices are as follows: Hang Seng Innovation Drug Index at 56.7x, CSI Hong Kong Pharmaceutical and Health Comprehensive Index at 29.2x, CSI Innovation Drug Industry Index at 52.8x, CSI Biotechnology Theme Index at 58.3x, and CSI 300 Pharmaceutical and Health Index at 32.6x [3][6]. Recent Transactions - In August, several Chinese pharmaceutical companies announced significant patent licensing deals. Fosun Pharma's subsidiary entered into a licensing agreement with Sitala for the small molecule inhibitor FXS6837, involving a $190 million upfront payment, $5 million in equity, and up to $480 million in sales milestone payments. Additionally, Rongchang Bio and Santen Pharmaceuticals reached a licensing agreement for the RC28-E injection, with a 250 million yuan upfront payment and potential milestone payments totaling up to 525 million yuan [1].